Source: http://www.google.com/patents/US20050081847?dq=645576
Timestamp: 2017-05-26 10:13:02
Document Index: 129435718

Matched Legal Cases: ['§119', 'art 1040', 'art 1040', 'art 1040', 'art 1040', 'art 1040', 'art 1040', 'art 1101', 'art 590', 'art 1101', 'art 1101']

Patent US20050081847 - Automatic activation of medical processes - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsSystems and methods involve automatic activation, de-activation or modification of therapies or other medical processes based on brain state. A medical system includes a sensor system having one or more sensors configured to sense signals related to the brain state of the patient. A brain state analyzer...http://www.google.com/patents/US20050081847?utm_source=gb-gplus-sharePatent US20050081847 - Automatic activation of medical processesAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS20050081847 A1Publication typeApplicationApplication numberUS 10/922,663Publication dateApr 21, 2005Filing dateAug 20, 2004Priority dateSep 18, 2003Also published asUS7668591, US8380296, US20100106211Publication number10922663, 922663, US 2005/0081847 A1, US 2005/081847 A1, US 20050081847 A1, US 20050081847A1, US 2005081847 A1, US 2005081847A1, US-A1-20050081847, US-A1-2005081847, US2005/0081847A1, US2005/081847A1, US20050081847 A1, US20050081847A1, US2005081847 A1, US2005081847A1InventorsKent Lee, Jeffrey Stahmann, Jesse Hartley, Quan NiOriginal AssigneeKent Lee, Stahmann Jeffrey E., Hartley Jesse W., Quan NiExport CitationBiBTeX, EndNote, RefManPatent Citations (88), Referenced by (162), Classifications (38), Legal Events (3) External Links: USPTO, USPTO Assignment, EspacenetAutomatic activation of medical processes
US 20050081847 A1Abstract
Systems and methods involve automatic activation, de-activation or modification of therapies or other medical processes based on brain state. A medical system includes a sensor system having one or more sensors configured to sense signals related to the brain state of the patient. A brain state analyzer detects various brain states, including sleep stage and/or brain seizures. A controller uses the brain state detection information to control a medical system configured to perform at least one respiratory or cardiac process. Methods involve sensing signals related to brain state and determining the brain state of a patient based on the sensed signals. At least one respiratory or cardiac medical process is controlled based on the patient's brain state. Images(19) Claims(20)
RELATED PATENT DOCUMENTS [0001] This application claims the benefit of Provisional Patent Application Ser. No. 60/504,381, filed on Sep. 18, 2003, to which priority is claimed pursuant to 35 U.S.C. §119(e) and which is hereby incorporated herein by reference in its entirety.
FIELD OF THE INVENTION [0002] The invention relates generally to implantable medical monitoring and/or stimulation systems and methods, and more particularly to monitoring and/or stimulation systems and methods that activate therapy based on brain activity. BACKGROUND OF THE INVENTION [0003] Disordered breathing refers to a wide spectrum of respiratory conditions that involve disruption of the normal respiratory cycle. Although disordered breathing typically occurs during sleep, the condition may also occur while the patient is awake. Unfortunately, disordered breathing is often undiagnosed. If left untreated, the effects of disordered breathing may result in serious health consequences for the patient. [0004] Various types of disordered respiration have been identified, including, for example, apnea, hypopnea, dyspnea, hyperpnea, tachypnea, and periodic breathing, including Cheyne-Stokes respiration (CSR). Apnea is a fairly common disorder characterized by periods of interrupted breathing. Apnea is typically classified based on its etiology. One type of apnea, denoted obstructive apnea, occurs when the patient's airway is obstructed by the collapse of soft tissue in the rear of the throat. Central apnea is caused by a derangement of the central nervous system control of respiration. The patient ceases to breathe when control signals from the brain to the respiratory muscles are absent or interrupted. Mixed apnea is a combination of the central and obstructive apnea types. Regardless of the type of apnea, people experiencing an apnea event stop breathing for a period of time. The cessation of breathing may occur repeatedly during sleep, sometimes hundreds of times a night and sometimes for a minute or longer. [0005] Periodic breathing is characterized by cyclic respiratory patterns that may exhibit rhythmic rises and falls in tidal volume. Cheyne-Stokes respiration is a specific form of periodic breathing wherein the tidal volume decreases to zero resulting in apneic intervals. The breathing interruptions of periodic breathing and CSR may be associated with central apnea, or may be obstructive in nature. CSR is frequently observed in patients with congestive heart failure (CHF) and is associated with an increased risk of accelerated CHF progression. Because of the cardiovascular implications, therapy for respiration-related sleep disorders is of particular interest. [0006] Disordered breathing affects a significant percentage of people. Sleep disordered breathing is particularly prevalent and is associated with excessive daytime sleepiness, systemic hypertension, increased risk of stroke, angina and myocardial infarction. Respiratory disruption may be particularly serious for patients concurrently suffering from cardiovascular deficiencies, such as congestive heart failure. SUMMARY OF THE INVENTION [0007] Embodiments of the invention involve automatic control of therapies or other medical processes based on brain activity. Automatic control may involve automatic activation, de-activation and/or modification of such therapies and processes. In accordance with an embodiment of the invention, a system includes a sensor system having one or more sensors configured to sense signals related to the brain activity of the patient. A brain activity analyzer detects various brain states, including, for example, sleep state/stage and/or brain seizures. The brain activity detector may also be configured to discriminate between sleep and wakefulness. A controller uses the brain state detection information to control a medical system configured to perform at least one respiratory or cardiac process. [0008] Other embodiments of the invention include at least one of an EEG sensor and an EMG sensor configured for one or more of detecting brain state. One or more sensors may be positioned on a respiratory mask of a respiratory device, such as a positive airway pressure therapy device. Further embodiments include a cardiac rhythm management device, wherein the cardiac process may involve one or both of a cardiac therapy process and a breathing therapy process. The cardiac process may further involve a diagnostic process and/or a monitoring process. [0009] In accordance with another embodiment of the invention, a method involves sensing signals related to brain state and determining the brain state of a patient based on the sensed signals. At least one respiratory or cardiac medical process is activated, de-activated, modified or otherwise controlled based on the patient's brain state. [0010] Further embodiments of methods in accordance with the invention involve sensing the signals related to brain state using EEG signals and/or EMG signals. Sensing signals related to brain state may further involve sensing signals related to sleep stage. Sensing signals related to brain state may involve sensing seizure, and activating the medical process may involve activating, de-activating, modifying or otherwise controlling arrhythmia therapy based on seizure detection. BRIEF DESCRIPTION OF THE DRAWINGS [0011] FIG. 1A is a flow chart illustrating a method of controlling a medical process using brain state information in accordance with embodiments of the invention; [0012] FIGS. 1B-1D are block diagrams of systems implementing control of medical processes using brain activity information in accordance with embodiments of the invention; [0013] FIG. 1E illustrates graphs of signals from an EEG sensor and an EMG sensor useful for determining brain state in accordance with embodiments of the invention; [0014] FIGS. 1F-1H and 1J are diagrams illustrating various configurations of sensors coupled to an implanted medical device that uses brain state information to activate, de-activate, and/or modify therapy in accordance with embodiments of the invention; [0015] FIG. 2 is a flow chart illustrating a brain state algorithm based on signals from an EEG sensor in accordance with embodiments of the invention; [0016] FIG. 3 is a graph of a normal respiration signal measured by a transthoracic impedance sensor that may be utilized for monitoring, diagnosis and/or therapy in accordance with embodiments of the invention; [0017] FIG. 4 is a respiration signal graph illustrating respiration intervals used for disordered breathing detection according to embodiments of the invention; [0018] FIG. 5 is a graph of a respiration signal illustrating various intervals that may be used for detection of apnea in accordance with embodiments of the invention; [0019] FIG. 6 is a respiration graph illustrating abnormally shallow respiration utilized in detection of disordered breathing in accordance with embodiments of the invention; [0020] FIG. 7 is a flow chart illustrating a method of apnea and/or hypopnea detection according to embodiments of the invention; [0021] FIG. 8 illustrates a medical system including an implantable cardiac rhythm management device that cooperates with a patient-external respiration therapy device to provide coordinated patient monitoring, diagnosis and/or therapy using brain state information in accordance with an embodiment of the invention; [0022] FIG. 9 is an illustration of an implantable cardiac device including a lead assembly shown implanted in a sectional view of a heart, the device used for coordinated patient monitoring, diagnosis, and/or therapy using brain state information in accordance with embodiments of the invention; [0023] FIG. 10 is an illustration of a thorax having an implanted subcutaneous medical device that may be used for coordinated patient monitoring, diagnosis, and/or therapy using brain state information in accordance with an embodiment of the invention; [0024] FIG. 11 is a block diagram of a cardiac rhythm management (CRM) system configured as a pacemaker and suitable for implementing a sleep detection methodology in accordance with embodiments of the invention; and [0025] FIG. 12 is a block diagram of a medical system that may be used to implement coordinated patient monitoring, diagnosis, and/or therapy using brain state information in accordance with embodiments of the invention.
[0026] While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail below. It is to be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims. DETAILED DESCRIPTION OF VARIOUS EMBODIMENTS [0027] In the following description of the illustrated embodiments, references are made to the accompanying drawings, which form a part hereof, and in which are shown by way of illustration, various embodiments by which the invention may be practiced. It is to be understood that other embodiments may be utilized, and structural and functional changes may be made without departing from the scope of the invention. [0028] Detection of brain state may be used to trigger sleep-time therapy in a respiratory and/or cardiac device. A patient's brain state may be determined by sensing brain activity of the patient, which may provide normal brain state information such as sleep state/stage, as well as abnormal brain state information such as seizure information. It may also be useful to trigger patient monitoring and/or data collection for diagnostic purposes during sleep. Data acquired during sleep may assist in diagnosing various sleep-related disorders. The collected data may be stored, displayed, printed, or transmitted to a separate device. [0029] Embodiments of the invention include automatic activation, de-activation and/or modification of therapy based on sleep stage. Alternatively, or additionally, sleep stage information may be used to automatically activate, de-activate and/or modify a number of processes, including for example, patient monitoring processes and/or diagnostic processes. Therapies may be selectively activated, de-activated, and/or modified based on sleep stage. For example, during deeper sleep stages, less invasive therapies such as a pacing therapy may be more desirable than a CPAP therapy. Embodiments may further provide for discrimination between sleep and wakefulness. [0030] A number of disorders, for example, sleep disordered breathing and movement disorders such as Periodic Limb Movement Disorder (PLMD), occur primarily while the patient is asleep. It may be useful to provide a first therapy while the patient is awake and to trigger a second therapy while the patient is asleep using brain state information. [0031] Other embodiments of the invention include a device that detects brain state, such as by using EEG sensor information, and based on the detected brain state, initiates, de-activates or alters therapy provided by a CRM device and/or a respiratory device. This allows closed loop control of sleep-disordered breathing based on sleep stage, which may be determined from the EEG sensor information. The EEG sensor information may also be used to detect seizures, and based on seizure detection, control CRM therapy to treat potential arrhythmias. [0032] A significant percentage of patients between the ages of 30 and 60 years experience some symptoms of disordered breathing. Although disordered breathing may occur while the patient is awake, it more often occurs during sleep. Sleep disordered breathing is associated with excessive daytime sleepiness, systemic hypertension, increased risk of stroke, angina and myocardial infarction. Disordered breathing is particularly prevalent among congestive heart failure patients, and may contribute to the progression of heart failure. [0033] Various therapies have been used to treat central and/or obstructive disordered breathing episodes. Obstructive sleep apnea has been associated with prolapse of the tongue and its surrounding structure into the pharynx, thus occluding the respiratory pathway. A commonly prescribed treatment for obstructive apnea is continuous positive airway pressure (CPAP). A CPAP device delivers air pressure through a nasal mask worn by the patient. The application of continuous positive airway pressure keeps the patient's throat open, reducing or eliminating the obstruction causing apnea. The term xPAP will be used herein as a generic term for any method, system, or device useful for treatment of apnea, including devices using forms of positive airway pressure, whether continuous pressure or variable pressure, as well as gas therapy and/or oxygen therapy devices. [0034] Cardiac stimulation may alternately or additionally be used as a therapy for disordered breathing. Therapy methods for disordered breathing based on cardiac electrical stimulation are described in commonly owned U.S. patent application Ser. No. 10/643,203 (Docket Number GUID.059PA), filed on Aug. 18, 2003, and U.S. patent application Ser. No. 10/643,154 (Docket Number GUID.103PA), filed on Aug. 18, 2003 both of which are incorporated by reference herein. [0035] Disorders and diseases affecting the interdependent physiological systems of the human body may be more effectively diagnosed and treated using a coordinated approach. Various embodiments of the invention are implemented using medical systems employing one or a number of patient-external and/or patient-internal medical systems. Medical systems may communicate or otherwise operate in concert or in a stand-alone manner to provide more comprehensive patient monitoring, diagnosis, and therapy. [0036] The following discussion, with reference to FIGS. 1A-1H and 1J, describes embodiments of the invention involving automatic activation, deactivation, modification and/or control of therapy based on sleep stage. Sleep staging may be detected using various approaches, including, for example, by detecting brain activity, skeletal muscle movement, heart rate or other cardiac timing or intervals (e.g., PR interval), respiratory patterns, and/or other activity/signal that can be used as a surrogate measurement of sleep. The processes and systems exemplified by these embodiments may be implemented alone or in combination with one or more processes and systems exemplified by other embodiments described herein to provide a coordinated approach to patient monitoring, diagnosis, and/or therapy. [0037] Although disordered breathing may occur while the patient is awake, the disorder is much more prevalent while the patient is sleeping. In various embodiments of the invention, sleep stage information is used to enhance sleep disordered breathing therapy and/or diagnosis of a variety of sleep related disorders. [0038] In accordance with one embodiment, sleep stage detection may be used to trigger therapy for disordered breathing. Using this approach, administration of disordered breathing therapy may be coordinated with a particular sleep stage. For example, disordered breathing episodes are typically more frequent during stage 1 or stage 2 sleep. The system may use sleep stage detection to deliver the therapy during these sleep stages. REM sleep and sleep stages 3 and 4 are the most restful sleep stages, therefore it is desirable to avoid interruption of sleep during these stages. The system may terminate or reduce the level of therapy during REM sleep and sleep stages 3 and 4 when avoidance of sleep interruptions are most desirable. [0039] Sleep stage detection may be accomplished using a number of techniques, including, for example, a technique using muscle atonia sensors described in commonly owned U.S. patent application Ser. No. 10/643,006, filed Aug. 18, 2003, entitled “Sleep State Classification,” which is hereby incorporated herein by reference. Sleep stage detection may also be effected using patient-internal or patient-external sensors, including, for example EEG sensors and/or EMG sensors. In one configuration, the sensors, e.g., EEG and/or EMG sensors, used in combination with a respiratory therapy device, such as an xPAP device, may be positioned on the xPAP mask. Sleep stage detection may also be derived from heart rate, cardiac PR intervals (or other cardiac timing), tidal volume, respiratory rate, minute ventilation, body core temperature, or other physiological measurements that are affected by autonomic control. [0040] Sleep stage information may also be valuable in the context of diagnosing various disorders, including sleep-related disorders. In accordance with one embodiment, sleep information, including sleep onset, offset, sleep stages, sleep efficiency, sleep latency, and the number and degree of arousals may be collected by the system for storage, display, or transmission to a remote device. The sleep-related information may be evaluated along with information about detected disordered breathing episodes to more fully understand how sleep disordered breathing affects a particular patient. The use of EEG sensors also allows detection of abnormal brain activity, including seizures. The EEG sensor information may be collected and used for a variety of diagnostic and therapeutic purposes. [0041] FIG. 1A is a flow chart illustrating a system 50 useful for activating, de-activating or modifying a medical process using brain state information in accordance with embodiments of the invention. The system 50 involves sensing brain activity with a sensor 60, either directly, such as by using an EEG sensor to measure brain-waves, or indirectly, such as by using an EMG sensor to measure muscular response to neurostimulation. A brain activity detector 65 receives information from the sensor 60 and determines a brain state, which is used by a controller 70. The controller 70 may control one or both of an implantable medical device 72 and a respiratory therapy unit 74. The implantable medical device 72 and/or the respiratory therapy unit 74 provides therapy based on information about the sensed brain activity. [0042] A system utilizing sleep stage sensors in connection with the control of diagnostic and/or therapeutic functions of a disordered breathing system in accordance with an embodiment of the invention is illustrated in FIG. 1B. In this embodiment, patient-internal or patient-external sensors 104, for example EEG and/or EMG sensors, are coupled to a therapy device 101. The therapy device 101 includes a sleep stage processor 102 that analyzes the sensor signals to detect the patient's sleep state, including sleep offset, onset, and stages of sleep. [0043] The sleep stage processor 102 is coupled to a therapy control unit 103. The therapy control unit 103 may control various types of therapy, including, for example, disordered breathing therapy, cardiac pacing therapy, respiratory therapy, electrical stimulation therapy, muscle stimulation therapy, nerve stimulation therapy, and/or pharmacological therapy, among other therapy types. The therapy control unit 103 uses the sleep information to initiate, terminate or adjust therapy to the patient based on the patient's sleep stage. [0044] The therapy device 101 may further include a memory 104 that receives and stores information from the sleep stage processor 102, the sensors 104 and/or other components. The information stored in the memory 105 may be displayed and/or downloaded to a remote device, or used for a variety of diagnostic purposes. [0045] Another embodiment of the invention is illustrated in FIG. 1C. In accordance with this embodiment, a first therapy device 170 is used to control therapy delivery of a second therapy device 190. The first therapy device 170 includes a sleep stage processor 172 coupled to sensors 180, e.g., EEG and/or EMG sensors. The sleep stage processor receives signals from the sensors 180 and analyzes the sensor signals to determine sleep onset, offset, and stages of sleep. [0046] Sleep stage information is transferred from the sleep stage processor 172 to a first therapy control unit 174 and a second therapy control unit 176. The therapy control units 174, 176 use the sleep stage information to initiate, terminate or modify the therapy delivered by the first and the second therapy devices 170, 190, respectively, based on the patient's sleep state. [0047] The first therapy device 170 may also include a memory 177 that receives and stores information from the sleep stage processor 172, the sensors 180 and/or other components. The information stored in the memory 177 may be displayed and/or downloaded to a remote device, or used for a variety of diagnostic purposes. [0048] A further embodiment of the invention is illustrated in FIG. 1D. According to this embodiment, first and second therapy devices 110, 130 deliver first and second therapies to a patient. The first therapy device 110 may be implemented as a CRM device, providing cardiac pacing and/or defibrillation therapies to treat various arrhythmias and/or to provide resynchronization therapy, for example. The CRM device 110 may also deliver electrical stimulation therapy to the heart to treat disordered breathing. [0049] The second therapy device 130 may be implemented as respiratory therapy device, such as an xPAP device. The xPAP device 130 delivers air or other gas therapy at a controlled pressure to the patient's airway. [0050] EEG sensors 120 are coupled to a sleep stage processor 160 located in the CRM device 110. Other sensors, such as EMG sensors, may also be included. Signals from the EEG and/or other sensors 120 are analyzed by the sleep stage processor 160 to determine various stages of sleep, including sleep onset, offset, sleep stage, the number and frequency of arousals, and the degree of arousal. [0051] Information from the sleep stage processor 160 is provided to the respiratory therapy controller 150 located in the CRM device 110. The respiratory therapy controller 150 uses the sleep stage information to initiate, terminate, or modify the respiratory therapy based on the sleep stage. [0052] Information from the sleep stage processor 160 and a brain wave analyzer 162 is provided to the CRM therapy controller 140. The CRM therapy controller 140 includes a disordered breathing (DB) therapy control unit 142 that uses the sleep stage information to initiate, terminate, or modify electrical stimulation DB therapy delivered by the CRM device 110 based on the patient's sleep state. [0053] The CRM therapy controller 140 may further include an arrhythmia therapy control unit 144. Information from the sleep stage processor 160 and the brain wave analyzer 162 may be used by the arrhythmia therapy control unit to 144 initiate, terminate, or modify arrhythmia therapy delivered to the patient. [0054] For example, the CRM therapy controller 140 may decrease the cardiac pacing rate to a sleep rate upon sleep onset and raise the pacing rate at sleep offset. Further, the CRM therapy controller 140 may adjust the pacing therapy delivered to the patient during proarrhythmic sleep periods, such as REM sleep or the during morning arousal. In one example, the arrhythmia therapy control unit 144 may deliver atrial overdrive pacing during proarrhythmic sleep periods to prevent the occurrence of arrhythmia. [0055] The EEG sensor signals may also be used by a brain wave analyzer 162 to evaluate brain activity. The brain wave analyzer 162 detects abnormal brain activity, such as seizures. Patients may have seizures during the night and not realize that the seizures have occurred. Some seizures are accompanied by cardiac rhythm disturbances. The brain wave analyzer 162 may detect the occurrence of seizures and provide information about the seizures to the arrhythmia therapy control unit 144. The arrhythmia therapy control unit 144 may modify the CRM therapy to treat cardiac rhythm disturbances cause by, or associated with, seizures. The arrhythmia therapy control unit 144 may also withhold therapy for rhythm disturbances that are associated with seizures. [0056] The CRM device 110 may include a memory 164 for storing information from the sleep stage processor 160, the brain wave analyzer 162 and other components of the CRM device 110. Stored information may be transferred to a display or other device. [0057] Autonomic arousal responses, as detected using EEG sensors and EMG sensors, are indicative of brain state. Referring now to FIG. 1E, a sleep study sensor array output is illustrated including an apnea event terminating in an arousal. Arousal may be detected from changes in the sympathetic or parasympathetic nervous system. These changes may be either short-term (i.e., changes associated with individual arousals) or long-term (i.e., aggregate effect of multiple arousals). A short-term effect of arousal includes, for example, the activation of sympathetic nerve activities. Sympathetic or parasympathetic changes, or the changes of autonomic balance, may be assessed, for example, by heart rate variability (HRV), which may be readily detected using a CRM device. [0058] Arousal information may be also used by the sleep stage processor 160 to augment disordered breathing detection. For example, arousal information may be used to confirm occurrences of disordered breathing. Arousal information may be used to distinguish between correctly and incorrectly identified disordered breathing occurrences indicated by the disordered breathing detector. Further, information from arousal detection may be used to separate disordered breathing episodes, e.g., apnea and/or hypopnea, followed by arousal versus those terminated without arousal. The disordered breathing events that are followed by arousal are considered to be the most disruptive, as these arousals interrupt the normal course of sleep and prevent the patient from receiving a full sleep cycle each night. Detecting these types of disordered breathing events may enhance the specificity of disordered breathing detection. Further description of the use of arousal information in combination with cardiac and xPAP therapies is described in commonly-owned, U.S. patent application identified by Attorney Docket No. GUID.106PA and entitled “Autonomic Arousal Detection System and Method,” filed on Aug. 17, 2004 and hereby incorporated herein by reference. [0059] In the graphs of FIG. 1E, the abscissa of all the graphs is the same time period during the sleep analysis of a patient. The ordinate of each of the graphs is the signal amplitude of the respective sensor. Traces 205, 210, 215, and 220 are the top, second, third, and fourth traces respectively, plotted from electrodes adapted to produce electroencephalograms (EEG). Evident in all four traces, but particularly pointed out in traces 205 and 210 is an EEG detected arousal 265. A trace 225 provides an electrocardiogram (EKG) of the heartbeats during the time period of the graph. A trace 230 provides an electromyogram defining muscular movement during the time period of the graph. Particularly evident in the trace 230 are arousals indicated by an arousal on EMG 260. [0060] Traces 235, 240, 245, and 250 depict pulmonary activity as sensed by bands placed around the torso. For example, trace 240 is produced using a band encircling the thorax of the patient, and trace 250 is produced using a band encircling the abdomen of the patient. Pulmonary activity may also be sensed through the use of internal sensors, such as, for example, thoracic impedance sensors and minute ventilation sensors as will be described further below. Trace 255 depicts the blood oxygen saturation level of the patient. [0061] FIGS. 1F-1H and 1J illustrate various configurations of an EMG sensor mechanically coupled to an implanted medical device 320, such as an implantable pacemaker or implantable cardioverter/defibrillator in accordance with embodiments of the invention, which may be useful for indirectly detecting brain state and activating, de-activating or modifying medical processes, such as by detecting arousal, sleep-state, seizure, or other indirect detection of brain state and/or brain activity. The implantable medical device 320 may include a housing 322 enclosing the medical device circuitry and a header 324 for coupling a lead system 340 to the circuitry of the medical device 320. [0062] An EMG sensor may be implemented, for example, using an electromyogram (EMG) electrode 326 or force responsive sensor 330 positioned on the housing 322 of the medical device 320 as illustrated in FIGS. 1H and 1J, respectively. FIG. 1H illustrates an EMG sensor 328 positioned on the header 324 of the medical device 320. Alternatively, an EMG sensor 342, e.g., EMG electrode or strain gauge, may be positioned on the lead system 340 or may be coupled to the housing 322 through a catheter or lead system 340, such as by using the header 324, as illustrated in FIG. 1J. [0063] FIG. 2 illustrates a method 400 for implantably sensing and detecting brain state. A brain state sense signal is sensed at a block 402. Brain state may be sensed, for example, directly using EEG sensors, and/or indirectly using ECG sensors, EEG sensors, EMG sensors, transthoracic impedance sensors, or other sensors suitable for determining patient brain state. If the patient is sleeping, brain state may be detected using the brain state sense signal illustrated by determination block 404. [0064] The brain state detected at determination block 404 provides various types of information recorded at block 406. For example, date, time, sensor data, sense signal amplitudes and/or cycle lengths. This and other information may be useful for updating, developing, and/or determining an arousal index, an apnea/hypopnea index, a composite index and other parameters useful for patient diagnosis and treatment, such as the automatic activation, de-activation or modification of medical processes. This information may be useful for detecting abnormal brain activity, such as seizures. The information recorded at block 406 may be useful, for example, to predict, verify, classify, and/or determine the severity of a disordered breathing episode and abnormal brain activity. [0065] If intervention and/or treatment is desired at determination block 408, the intervention and/or treatment may be performed at block 410 before re-starting the method 400. For example, the intervention at block 410 may be the automatic activation of a medical process, modification of a patient's CRM stimulation, modification of a disordered breathing therapy, or other desirable action. [0066] Referring now to FIG. 3, an impedance signal 500 is illustrated. Transthoracic impedance may be useful for detecting sleep-state and other indirect measurements of brain activity, such as seizures, as well as breathing disorders. The impedance signal 500 may be developed, for example, from an impedance sense electrode in combination with a CRM device. The impedance signal 500 is proportional to the transthoracic impedance, illustrated as an Impedance 530 on the abscissa of the left side of the graph in FIG. 3. [0067] The impedance 530 increases during any respiratory inspiration 520 and decreases during any respiratory expiration 510. The impedance signal 500 is also proportional to the amount of air inhaled, denoted by a tidal volume 540, illustrated on the abscissa of the right side of the graph in FIG. 3. The variations in impedance during respiration, identifiable as the peak-to-peak variation of the impedance signal 500, may be used to determine the respiration tidal volume 540. Tidal volume 540 corresponds to the volume of air moved in a breath, one cycle of expiration 510 and inspiration 520. A minute ventilation may also be determined, corresponding to the amount of air moved per a minute of time 550 illustrated on the ordinate of the graph in FIG. 3. [0068] The onset of breathing disorders may be determined using the impedance signal 530, and detected breathing disorder information may be used to activate or modify therapy in accordance with the present invention. During non-REM sleep, a normal respiration pattern includes regular, rhythmic inspiration-expiration cycles without substantial interruptions. When the tidal volume of the patient's respiration, as indicated by the transthoracic impedance signal, falls below a hypopnea threshold, then a hypopnea event is declared. For example, a hypopnea event may be declared if the patient's tidal volume falls below about 50% of a recent average tidal volume or other baseline tidal volume value. If the patient's tidal volume falls further to an apnea threshold, e.g., about 10% of the recent average tidal volume or other baseline value, an apnea event is declared. [0069] An adequate quality and quantity of sleep is required to maintain physiological homeostasis. Prolonged sleep deprivation or periods of highly fragmented sleep ultimately has serious health consequences. Chronic lack of sleep may be associated with various cardiac or respiratory disorders affecting a patient's health and quality of life. Methods and systems for collecting and assessing sleep quality data are described in commonly owned U.S. patent application Ser. No. 10/642,998, entitled “Sleep Quality Data Collection and Evaluation,” filed on Aug. 18, 2003, and incorporated herein by reference in its entirety. Evaluation of the patient's sleep patterns and sleep quality may be an important aspect of providing coordinated therapy to the patient, including respiratory and cardiac therapy. [0070] FIGS. 4-6 are graphs of transthoracic impedance and tidal volume, similar to FIG. 3 previously described. As stated earlier, using transthoracic impedance is one indirect method of determining brain state, such as by detecting sleep state, arousal, and disordered breathing, for example. As in FIG. 3, FIGS. 4-6 illustrate the impedance signal 500 proportional to the transthoracic impedance, again illustrated as Impedance 530 on the abscissa of the left side of the graphs in FIGS. 4-6. The impedance 530 increases during any respiratory inspiration 520 and decreases during any respiratory expiration 510. As before, the impedance signal 500 is also proportional to the amount of air inhaled, denoted the tidal volume 540, illustrated on the abscissa of the right side of the graph in FIGS. 4-6. The magnitude of variations in impedance and tidal volume during respiration are identifiable as the peak-to-peak variation of the impedance signal 500. [0071] FIG. 4 illustrates respiration intervals used for disordered breathing detection useful in accordance with embodiments of the invention. Respiration intervals are used to detect apnea and hypopnea, as well as provide other sleep-state information for activating, de-activating or modifying therapy in accordance with the present invention. Detection of disordered breathing may involve defining and examining a number of respiratory cycle intervals. A respiration cycle is divided into an inspiration period corresponding to the patient inhaling, an expiration period, corresponding to the patient exhaling, and a non-breathing period occurring between inhaling and exhaling. Respiration intervals are established using an inspiration threshold 610 and an expiration threshold 620. The inspiration threshold 610 marks the beginning of an inspiration period 630 and is determined by the transthoracic impedance signal 500 rising above the inspiration threshold 610. The inspiration period 630 ends when the transthoracic impedance signal 500 is a maximum 640. The maximum transthoracic impedance signal 640 corresponds to both the end of the inspiration interval 630 and the beginning of an expiration interval 650. The expiration interval 650 continues until the transthoracic impedance 500 falls below an expiration threshold 620. A non-breathing interval 660 starts from the end of the expiration period 650 and continues until the beginning of a next inspiration period 670. [0072] Detection of sleep apnea and severe sleep apnea is illustrated in FIG. 5. The patient's respiration signals are monitored and the respiration cycles are defined according to an inspiration 730, an expiration 750, and a non-breathing 760 interval as described in connection with FIG. 4. A condition of sleep apnea is detected when a non-breathing period 760 exceeds a first predetermined interval 790, denoted the sleep apnea interval. A condition of severe sleep apnea is detected when the non-breathing period 760 exceeds a second predetermined interval 795, denoted the severe sleep apnea interval. For example, sleep apnea may be detected when the non-breathing interval exceeds about 10 seconds, and severe sleep apnea may be detected when the non-breathing interval exceeds about 20 seconds. [0073] Hypopnea is a condition of disordered breathing characterized by abnormally shallow breathing. Hypopnea reduces oxygen to the brain, and is linked with altered brain activity and brain states. The altered brain activity and brain states indicative of hypopnea may be used to activate or modify therapy in accordance with the present invention. FIG. 6 is a graph of tidal volume derived from transthoracic impedance measurements. The graph of FIG. 6 illustrating the tidal volume of a hypopnea episode may be compared to the tidal volume of a normal breathing cycle illustrated previously in FIG. 2, which illustrated normal respiration tidal volume and rate. As shown in FIG. 6, hypopnea involves a period of abnormally shallow respiration, possible at an increased respiration rate. [0074] Hypopnea is detected by comparing a patient's respiratory tidal volume 803 to a hypopnea tidal volume 801. The tidal volume for each respiration cycle may be derived from transthoracic impedance measurements acquired in the manner described previously. The hypopnea tidal volume threshold may be established by, for example, using clinical results providing a representative tidal volume and duration of hypopnea events. In one configuration, hypopnea is detected when an average of the patient's respiratory tidal volume taken over a selected time interval falls below the hypopnea tidal volume threshold. Furthermore, various combinations of hypopnea cycles, breath intervals, and non-breathing intervals may be used to detect hypopnea, where the non-breathing intervals are determined as described above. [0075] In FIG. 6, a hypopnea episode 805 is identified when the average tidal volume is significantly below the normal tidal volume. In the example illustrated in FIG. 6, the normal tidal volume during the breathing process is identified as the peak-to peak value identified as the respiratory tidal volume 803. The hypopnea tidal volume during the hypopnea episode 805 is identified as hypopnea tidal volume 801. For example, the hypopnea tidal volume 801 may be about 50% of the respiratory tidal volume 803. The value 50% is used by way of example only, and determination of thresholds for hypopnea events may be determined as any value appropriate for a given patient. In the example above, if the tidal volume falls below 50% of the respiratory tidal volume 803, the breathing episode may be identified as a hypopnea event, originating the measurement of the hypopnea episode 805. [0076] FIG. 7 is a flow chart illustrating a method of apnea and/or hypopnea detection useful for activating, de-activating or modifying therapy based on brain activity in accordance with embodiments of the invention. Various parameters are established 901 before analyzing the patient's respiration for disordered breathing episodes, including, for example, inspiration and expiration thresholds, sleep apnea interval, severe sleep apnea interval, and hypopnea tidal volume (TV) threshold. [0077] The patient's transthoracic impedance is measured 905 as described in more detail above. If the transthoracic impedance exceeds 910 the inspiration threshold, the beginning of an inspiration interval is detected 915. If the transthoracic impedance remains below 910 the inspiration threshold, then the impedance signal is checked 905 periodically until inspiration 915 occurs. [0078] During the inspiration interval, the patient's transthoracic impedance is monitored until a maximum value of the transthoracic impedance is detected 920. Detection of the maximum value signals an end of the inspiration period and a beginning of an expiration period 935. [0079] The expiration interval is characterized by decreasing transthoracic impedance. When, at determination 940, the transthoracic impedance falls below the expiration threshold, a non-breathing interval is detected 955. [0080] If the transthoracic impedance determination 960 does not exceed the inspiration threshold within a first predetermined interval, denoted the sleep apnea interval 965, then a condition of sleep apnea is detected 970. Severe sleep apnea 980 is detected if the non-breathing period extends beyond a second predetermined interval, denoted the severe sleep apnea interval 975. [0081] When the transthoracic impedance determination 960 exceeds the inspiration threshold, the tidal volume from the peak-to-peak transthoracic impedance is calculated, along with a moving average of past tidal volumes 985. The peak-to-peak transthoracic impedance provides a value proportional to the tidal volume of the respiration cycle. This value is compared at determination 990 to a hypopnea tidal volume threshold. If, at determination 990, the peak-to-peak transthoracic impedance is consistent with the hypopnea tidal volume threshold for a predetermined time 992, then a hypopnea cycle 995 is detected. [0082] According to one embodiment of the invention, illustrated in FIG. 8, a medical system 1000 may include an implantable cardiac rhythm management device 1010 that cooperates with a patient-external respiration therapy device 1020 to provide coordinated patient monitoring, diagnosis and/or therapy. In the example illustrated in FIG. 8, a mechanical respiration therapy device, designated CPAP device 1020, includes a positive airway pressure device that cooperates with a CRM 1010. Positive airway pressure devices may be used to provide a variety of respiration therapies, including, for example, continuous positive airway pressure (CPAP), bi-level positive airway pressure (bi-level PAP), proportional positive airway pressure (PPAP), auto-titrating positive airway pressure, ventilation, gas or oxygen therapies. Such devices may also be configured to provide negative airway pressure on a selective basis as needed, such as in the treatment of Cheyne-Stokes breathing. These therapies may be activated, de-activated or adjusted based on brain state in accordance with the present invention. [0083] The CPAP device 1020 develops a positive air pressure that is delivered to the patient's airway through a tube system 1052 and a mask 1054 connected to the CPAP device 1020. The mask 1054 may include EEG sensors, such as an EEG sensor 1056 attached to a strap 1057 that is placed around a head 1055 of the patient. Positive airway pressure devices are often used to treat disordered breathing. In one configuration, for example, the positive airway pressure provided by the CPAP device 1020 acts as a pneumatic splint keeping the patient's airway open and reducing the severity and/or number of occurrences of disordered breathing due to airway obstruction. [0084] The CPAP device 1020 may directly control the delivery of respiration therapy to the patient, and may contribute to the control of the CRM device 1010. In addition, the CPAP device 1020 may provide a number of monitoring and/or diagnostic functions in relation to the respiratory system and/or other physiological systems. [0085] The CRM 1010 and CPAP 1020 devices may communicate directly through a wireless communications link 1017, for example. Alternatively, or additionally, the CRM 1010 and CPAP 1020 devices may communicate with and/or through an APM such as an APM system 1030, as will be described further below with reference to FIG. 12. The CRM 1010 may be coupled to a heart 1040 of the patient using a lead system 1015, for example. [0086] The CRM 1010 may provide a first set of monitoring, diagnostic, and/or therapeutic functions to a patient 1055. The CRM 1010 may be electrically coupled to a patient's heart 1040 through one or more cardiac electrodes 1015 terminating in, on, or about the heart 1040. The cardiac electrodes 1015 may sense cardiac signals produced by the heart 1040 and/or provide therapy to one or more heart chambers. For example, the cardiac electrodes 1015 may deliver electrical stimulation to one or more heart 1040 chambers, and/or to one or multiple sites within the heart 1040 chambers. The CRM 1010 may directly control delivery of one or more cardiac therapies, such as cardiac pacing, defibrillation, cardioversion, cardiac resynchronization, and/or other cardiac therapies, for example. In addition, the CRM 1010 may facilitate the control of a mechanical respiration device 1020. Further, the CRM 1010 may perform various monitoring and/or diagnostic functions in relation to the cardiovascular system and/or other physiological systems. [0087] Although FIG. 8 illustrates a CRM device 1010 used with a CPAP device 1020 to provide coordinated patient monitoring, diagnosis and/or therapy, any number of patient-internal and patient-external medical devices may be included in a medical system in accordance with the invention. For example, a drug delivery device, such as a drug pump or controllable nebulizer, may be included in the system 1000. The drug delivery device may cooperate with either or both of the CRM device 1010 and the CPAP device 1020 and may contribute to the patient monitoring, diagnosis, and/or therapeutic functions of the medical system 1000. [0088] FIG. 9 is a partial view of an implantable CRM device that may include circuitry 1104 to activate, deactivate, or modify therapies based on brain state in accordance with embodiments of the invention. In this example, the implantable CRM device comprises an implantable pulse generator 1100 electrically and physically coupled to an intracardiac lead system 1102. Portions of the intracardiac lead system 1102 are inserted into the patient's heart 1101. The intracardiac lead system 1102 includes one or more electrodes configured to sense electrical cardiac activity of the heart, deliver electrical stimulation to the heart, sense the patient's transthoracic impedance, and/or sense other physiological parameters, e,g, cardiac chamber pressure or temperature. Portions of the housing 1191 of the pulse generator 1100 may optionally serve as a can electrode. [0089] Communications circuitry is disposed within the housing 1191 for facilitating communication between the pulse generator 1100 and an external communication device, such as a portable or bed-side communication station, patient-carried/worn communication station, or external programmer, for example. The communications circuitry can also facilitate unidirectional or bidirectional communication with one or more implanted, external, cutaneous, or subcutaneous physiologic or non-physiologic sensors, patient-input devices and/or information systems. [0090] The pulse generator 1100 may optionally incorporate movement sensor 1192 that may be used o implement rate adaptive pacing. The movement sensor 1192 may be implemented as an accelerometer positioned in or on the housing 1191 of the pulse generator 1100. If the movement sensor 1192 is implemented as an accelerometer, the movement sensor 1192 may also provide respiratory, e.g. snoring, rales, coughing, and cardiac, e.g. S1-S4 heart sounds, murmurs, and other acoustic information. [0091] The lead system 1102 of the CRM device may incorporate one or more transthoracic impedance sensors that may be used to acquire the patient's respiration waveform, or other respiration-related information. The transthoracic impedance sensor may include, for example, one or more intracardiac electrodes 1116, 1114, 1154, 1156, 1112, 1117, 1113, 1161 positioned in one or more chambers of the heart 590. The intracardiac electrodes 1116, 1114, 1154, 1156, 1112, 1117, 1113, 1161 may be coupled to impedance drive/sense circuitry 1106 positioned within the housing 1191 of the pulse generator 1100. [0092] In one implementation, impedance drive/sense circuitry 1106 generates a current that flows through the tissue between an impedance drive electrode 1154 and a can electrode on the housing 1191 of the pulse generator 1100. The voltage at an impedance sense electrode 1156 relative to the can electrode changes as the patient's transthoracic impedance changes. The voltage signal developed between the impedance sense electrode 1156 and the can electrode is detected by the impedance sense circuitry 1106. Other locations and/or combinations of impedance sense and drive electrodes are also possible. [0093] The voltage signal developed at the impedance sense electrode 1156 is proportional to the patient's transthoracic impedance and represents the patient's respiration waveform. The transthoracic impedance increases during respiratory inspiration and decreases during respiratory expiration. The peak-to-peak transition of the transthoracic impedance is proportional to the amount of air moved in one breath, denoted the tidal volume. The amount of air moved per minute is denoted the minute ventilation. A normal “at rest” respiration pattern, e.g., during non-REM sleep, includes regular, rhythmic inspiration-expiration cycles without substantial interruptions. [0094] The lead system 1102 may include one or more cardiac pace/sense electrodes 1154, 1156, 1112, 1117, 1113 positioned in, on, or about one or more heart chambers for sensing electrical signals from the patient's heart 1101 and/or delivering pacing pulses to the heart 1101. The intracardiac sense/pace electrodes 1154, 1156, 1112, 1117, 1113, such as those illustrated in FIG. 9, may be used to sense and/or pace one or more chambers of the heart, including the left ventricle, the right ventricle, the left atrium and/or the right atrium. The lead system 1102 may include one or more defibrillation electrodes 1116, 1114 for delivering defibrillation/cardioversion shocks to the heart. [0095] The pulse generator 1100 may include circuitry for detecting cardiac arrhythmias and/or for controlling pacing or defibrillation therapy in the form of electrical stimulation pulses or shocks delivered to the heart through the lead system 1102. Circuitry 1104 for activating, deactivating, and/or modifying therapy based on brain state may be housed within the pulse generator 1100. The brain state activation circuitry 1104 may be coupled to various sensors, patient input devices, and/or other information systems through leads or through wireless communication links as described herein. [0096] FIG. 10 is a diagram illustrating a subcutaneous implantable medical device 1200 that may be used for detecting brain state and activating, deactivating or modifying medical processes in accordance with embodiments of the invention. The device 1200 illustrated in FIG. 10 is an ITCS device that may be implanted under the skin in the chest region of a patient. The ITCS device may, for example, be implanted subcutaneously such that all or selected elements of the device are positioned on the patient's front, back, side, or other body locations suitable for sensing cardiac activity and delivering cardiac stimulation therapy. It is understood that elements of the ITCS device may be located at several different body locations, such as in the chest, abdominal, or subclavian region with electrode elements respectively positioned at different regions near, around, in, or on the heart. [0097] The primary housing (e.g., the active or non-active can) of the ITCS device, for example, may be configured for positioning outside of a rib cage 1250 at an intercostal or subcostal location, within the abdomen, or in the upper chest region (e.g., subclavian location, such as above a third rib 1253). In one implementation, one or more electrodes may be located on a primary housing 1272 and/or at other locations about, but not in direct contact with the heart, great vessel or coronary vasculature. [0098] In another implementation, one or more electrodes may be located in direct contact with the heart, great vessel or coronary vasculature, such as via one or more leads implanted by use of conventional transvenous delivery approaches. In another implementation, for example, one or more subcutaneous electrode subsystems or electrode arrays may be used.to sense cardiac activity and deliver cardiac stimulation energy in an ITCS device configuration employing an active can or a configuration employing a non-active can. Electrodes may be situated at anterior and/or posterior locations relative to the heart. [0099] In particular configurations, systems and methods may perform functions traditionally performed by pacemakers, such as providing various pacing therapies as are known in the art, in addition to cardioversion/defibrillation therapies. Exemplary pacemaker circuitry, structures and functionality, aspects of which may be incorporated in an ITCS device of a type that may benefit from multi-parameter sensing configurations, are disclosed in commonly owned U.S. Pat. No. 4,562,841; 5,284,136; 5,376,476; 5,036,849; 5,540,727; 5,836,987; 6,044,298; and 6,055,454, which are hereby incorporated herein by reference in their respective entireties. It is understood that ITCS device configurations may provide for non-physiologic pacing support in addition to, or to the exclusion of, bradycardia and/or anti-tachycardia pacing therapies. [0100] An ITCS device in accordance with various embodiments may implement diagnostic and/or monitoring functions as well as provide cardiac stimulation therapy. Diagnostics functions may involve storing, trending, displaying, transmitting, and/or evaluating various indications based on the detection of EMG. Exemplary cardiac monitoring circuitry, structures and functionality, aspects of which may be incorporated in an ITCS of the invention, are disclosed in commonly owned U.S. Pat. No. 5,313,953; 5,388,578; and 5,411,031, which are hereby incorporated herein by reference in their respective entireties. [0101] An ITCS device may be used to implement various diagnostic functions, which may involve performing rate-based, pattern and rate-based, and/or morphological tachyarrhythmia discrimination analyses. Subcutaneous, cutaneous, and/or external sensors, such as those previously described, may be employed to acquire physiologic and non-physiologic information for purposes of enhancing tachyarrhythmia detection and termination. It is understood that configurations, features, and combination of features described in the present disclosure may be implemented in a wide range of implantable medical devices, and that such embodiments and features are not limited to the particular devices described herein. [0102] In FIG. 10, there is shown a configuration of a transthoracic cardiac sensing and/or stimulation (ITCS) device having components implanted in the chest region of a patient at different locations. In the particular configuration shown in FIG. 10, the ITCS device includes the housing 1272 within which various cardiac sensing, detection, processing, and energy delivery circuitry may be housed. It is understood that the components and functionality depicted in the figures and described herein may be implemented in hardware, software, or a combination of hardware and software. It is further understood that the components and functionality depicted as separate or discrete blocks/elements in the figures in general may be implemented in combination with other components and functionality, and that the depiction of such components and functionality in individual or integral form is for purposes of clarity of explanation, and not of limitation. [0103] Communications circuitry may be disposed within the housing 1272 for facilitating communication between the ITCS device and an external communication device, such as a portable or bedside communication station, patient-carried/worn communication station, or external programmer, for example. The communications circuitry may also facilitate unidirectional or bidirectional communication with one or more external, cutaneous, or subcutaneous physiologic or non-physiologic sensors. The housing 1272 is typically configured to include one or more electrodes (e.g., can electrode and/or indifferent electrode). Although the housing 1272 is typically configured as an active can, it is appreciated that a non-active can configuration may be implemented, in which case at least two electrodes spaced apart from the housing 1272 are employed. [0104] In the configuration shown in FIG. 10, a subcutaneous electrode 1274 may be positioned under the skin in the chest region and situated distal from the housing 1272. The subcutaneous and, if applicable, housing electrode(s) may be positioned about the heart at various locations and orientations, such as at various anterior and/or posterior locations relative to the heart. The subcutaneous electrode 1274 is coupled to circuitry within the housing 1272 via a lead assembly 1276. One or more conductors (e.g., coils or cables) are provided within the lead assembly 1276 and electrically couple the subcutaneous electrode 1274 with circuitry in the housing 1272. One or more sense, sense/pace or defibrillation electrodes may be situated on the elongated structure of the electrode support, the housing 1272, and/or the distal electrode assembly (shown as subcutaneous electrode 1274 in the configuration shown in FIG. 10). [0105] In one configuration, the electrode support assembly and the housing 1272 define a unitary structure (e.g., a single housing/unit). The electronic components and electrode conductors/connectors are disposed within or on the unitary ITCS device housing/electrode support assembly. At least two electrodes are supported on the unitary structure near opposing ends of the housing/electrode support assembly. The unitary structure may have an arcuate or angled shape, for example. [0106] According to another configuration, the electrode support assembly defines a physically separable unit relative to the housing 1272. The electrode support assembly includes mechanical and electrical couplings that facilitate mating engagement with corresponding mechanical and electrical couplings of the housing 1272. For example, a header block arrangement may be configured to include both electrical and mechanical couplings that provide for mechanical and electrical connections between the electrode support assembly and housing 1272. The header block arrangement may be provided on the housing 1272 or the electrode support assembly. Alternatively, a mechanical/electrical coupler may be used to establish mechanical and electrical connections between the electrode support assembly and housing 1272. In such a configuration, a variety of different electrode support assemblies of varying shapes, sizes, and electrode configurations may be made available for physically and electrically connecting to a standard ITCS device housing 1272. [0107] Various embodiments described herein may be used in connection with subcutaneous monitoring, diagnosis, and/or therapy. Methods, structures, and/or techniques described herein relating to subcutaneous systems and methods may incorporate features of one or more of the following references: commonly owned US Patent Applications: “Subcutaneous Cardiac Sensing, Stimulation, Lead Delivery, and Electrode Fixation Systems and Methods,” Ser. No. 60/462,272, filed Apr. 11, 2003; “Reconfigurable Subcutaneous Cardiac Device,” Ser. No: 10/821,248, filed: Apr. 8, 2004; and “Subcutaneous Cardiac Rhythm Management,” Ser. No: 10/820,642, filed: Apr. 8, 2004; each hereby incorporated herein by reference. [0108] Referring now to FIG. 11, there is shown a block diagram of an embodiment of a CRM system 1300 configured as a pacemaker and suitable for implantably detecting brain state and activating, de-activating or modifying medical processes in accordance with the invention. FIG. 11 shows the CRM 1300 divided into functional blocks. The CRM 1300 includes a sleep detector 1320 for receiving sleep-related signals and detecting sleep in accordance with embodiments of the invention. [0109] In one embodiment, the sleep detector 1320 is incorporated as part of CRM circuitry 1310 encased and hermetically sealed in a housing 1301 suitable for implanting in a human body. Power to the CRM 1300 is supplied by an electrochemical battery power supply 1312 housed within the CRM 1300. A connector block (not shown) is additionally attached to the CRM 1300 to allow for the physical and electrical attachment of the cardiac lead system conductors to the CRM circuitry 1310. [0110] The CRM circuitry 1310 may be configured as a programmable microprocessor-based system, with circuitry for detecting sleep in addition to providing pacing therapy to the heart. Cardiac signals sensed by one or more cardiac electrodes 1341 may be processed by the cardiac event detection circuitry 1360. Pace pulses controlled by the pacemaker control 1350 and generated by the pulse generator 1340 are delivered to the heart to treat various arrhythmias of the heart. [0111] The memory circuit 1316 may store parameters for various device operations involved in sleep detection and/or cardiac pacing and sensing. The memory circuit 1316 may also store data indicative of sleep-related signals received by components of the CRM circuitry 1310, such as information derived from one or more impedance electrodes 1395, the cardiac signal detector system 1360, the accelerometer 1335, and/or the sleep detector 1320. [0112] As illustrated in FIG. 11, the sleep detector 1320 receives signals derived from the cardiac event detector 1360, the impedance electrodes 1395 and the accelerometer 1335 to perform operations involving detecting sleep onset and sleep termination according to the principles of the invention. Historical data storage 1318 may be coupled to the sleep detection circuitry 1320 for storing historical sleep related data. Such data may be transmitted to an external programmer unit 1380 and used for various diagnostic purposes and as needed or desired. [0113] Telemetry circuitry 1314 is coupled to the CRM circuitry 1310 to allow the CRM 1300 to communicate with a remote device such as the programmer 1380, or other device such as a patient-external EEG sensor. In one embodiment, the telemetry circuitry. 1314 and the programmer 1380 use a wire loop antenna and a radio frequency telemetric link to receive and transmit signals and data between the programmer 1380 and telemetry circuitry 1314. In this manner, programming commands and data (such as EEG data) may be transferred between the CRM circuitry 1310 and the one or more remote devices 1380 during and after implant. [0114] The programming commands allow a physician to set or modify various parameters used by the CRM system 1300. These parameters may include setting sleep detection parameters for use during sleep detection, such as which sleep-related signals are to be used for sleep detection and threshold adjustment, and the initial sleep detection thresholds. In addition, the CRM system 1300 may download to the programmer 1380 stored data pertaining to sensed sleep periods, including the amount of time spent sleeping, the time of day sleep periods occurred, historical data of sleep times, and the number of arousals during the sleep periods, for example. [0115] Still referring to FIG. 11, signals associated with patient activity, indicative of brain state, may be detected through the use of an accelerometer 1335 positioned within the housing 1301 of the CRM 1300. The accelerometer 1335 may be responsive to patient activity. The accelerometer signal may be correlated with activity level or workload, for example. Signals derived from the accelerometer 1335 are coupled to the sleep detector 1320 and may also be used by the pacemaker 1350 for implementing a rate adaptive pacing regimen, for example. [0116] The impedance electrodes 1395 sense the patient's transthoracic impedance. As described earlier, transthoracic impedance may also be useful as an indirect measure of brain state. The transthoracic impedance may be used to calculate various parameters associated with respiration. Impedance driver circuitry (not shown) induces a current that flows through the blood between the impedance drive electrode and a can electrode on the housing 1301 of the CRM 1300. The voltage at an impedance sense electrode relative to the can electrode changes as the transthoracic impedance changes. The voltage signal developed between the impedance sense electrode and the can electrode is detected by the impedance sense amplifier and is delivered to the sleep detector circuitry 1320 for further processing. [0117] FIG. 12 is a block diagram of a medical system 1400 that may be used to implement coordinated patient measuring and/or monitoring, diagnosis, and/or therapy, including detecting EEG's and determining the brain state in accordance with embodiments of the invention. The medical system 1400 may include, for example, one or more patient-internal medical devices 1410 and one or more patient-external medical devices 1420. Each of the patient-internal 1410 and patient-external 1420 medical devices may include one or more of a patient monitoring unit 1412, 1422, a diagnostics unit 1414, 1424, and/or a therapy unit 1416, 1426. [0118] The patient-internal medical device 1410 is typically a fully or partially implantable device that performs measuring, monitoring, diagnosis, and/or therapy functions. The patient-external medical device 1420 performs monitoring, diagnosis and/or therapy functions external to the patient (i.e., not invasively implanted within the patient's body). The patient-external medical device 1420 may be positioned on the patient, near the patient, or in any location external to the patient. It is understood that a portion of a patient-external medical device 1420 may be positioned within an orifice of the body, such as the nasal cavity or mouth, yet may be considered external to the patient (e.g., mouth pieces/appliances, tubes/appliances for nostrils, or temperature sensors positioned in the ear canal). [0119] The patient-internal and patient-external medical devices 1410,1420 may be coupled to one or more sensors 1441, 1442, 1445, 1446, patient input devices 1443, 1447 and/or other information acquisition devices 1444, 1448. The sensors 1441, 1442, 1445, 1446, patient input devices 1443, 1447, and/or other information acquisition devices 1444, 1448 may be employed to detect conditions relevant to the monitoring, diagnostic, and/or therapeutic functions of the patient-internal and patient-external medical devices 1410, 1420. [0120] The medical devices 1410, 1420 may each be coupled to one or more patient-internal sensors 1441, 1445 that are fully or partially implantable within the patient. The medical devices 1410, 1420 may also be coupled to patient-external sensors positioned on, near, or in a remote location with respect to the patient. For example, the patient-external sensors 1442 may include EEG sensors useful for detecting brain activity. The patient-internal and patient-external sensors may also be used to sense conditions, such as physiological or environmental conditions, that affect the patient. [0121] The patient-internal sensors 1441 may be coupled to the patient-internal medical device 1410 through one or more internal leads 1453. In one example, as was described above with reference to FIG. 9, an internal endocardial lead system is used to couple cardiac electrodes to an implantable pacemaker or other cardiac rhythm management device. Still referring to FIG. 12, one or more patient-internal sensors 1441 may be equipped with transceiver circuitry to support wireless communications between the one or more patient-internal sensors 1441 and the patient-internal medical device 1410 and/or the patient-external medical device 1420. [0122] The patient-external sensors 1442 may be coupled to the patient-internal medical device 1410 and/or the patient-external medical device 1420 through one or more internal leads 1455 or through wireless connections. Patient-external sensors 1442 may communicate with the patient-internal medical device 1410 wirelessly. Patient-external sensors 1446 may be coupled to the patient-external medical device 1420 through one or more internal leads 1457 or through a wireless link. [0123] The medical devices 1410, 1420 may be coupled to one or more patient input devices 1443, 1447. The patient input devices are used to allow the patient to manually transfer information to the medical devices 1410, 1420. The patient input devices 1443, 1447 may be particularly useful for inputting information concerning patient perceptions, such as how well the patient feels, and information such as patient smoking, drug use, or other activities that are not automatically sensed or detected by the medical devices 1410, 1420. [0124] The medical devices 1410, 1420 may be connected to one or more information acquisition devices 1444, 1448, for example, a database that stores information useful in connection with the monitoring, diagnostic, or therapy functions of the medical devices 1410, 1420. For example, one or more of the medical devices 1410, 1420 may be coupled through a network to a patient information server 1430 that provides information about environmental conditions affecting the patient, e.g., the pollution index for the patient's location. [0125] In one embodiment, the patient-internal medical device 1410 and the patient-external medical device 1420 may communicate through a wireless link between the medical devices 1410, 1420. For example, the patient-internal and patient-external devices 1410, 1420 may be coupled through a short-range radio link, such as Bluetooth, IEEE 802.11, and/or a proprietary wireless protocol. The communications link may facilitate unidirectional or bidirectional communication between the patient-internal 1410 and patient-external 1420 medical devices. Data and/or control signals may be transmitted between the patient-internal 1410 and patient-external 1420 medical devices to coordinate the functions of the medical devices 1410, 1420. [0126] In another embodiment, the patient-internal and patient-external medical devices 1410,1420 may be used within the structure of an advanced patient management system 1440. Advanced patient management systems 1440 involve a system of medical devices that are accessible through various communications technologies. For example, patient data may be downloaded from one or more of the medical devices periodically or on command, and stored at the patient information server 1430. The physician and/or the patient may communicate with the medical devices and the patient information server 1430, for example, to acquire patient data or to initiate, terminate or modify therapy. [0127] The data stored on the patient information server 1430 may be accessible by the patient and the patient's physician through one or more terminals 1450, e.g., remote computers located in the patient's home or the physician's office. The patient information server 1430 may be used to communicate to one or more of the patient-internal and patient-external medical devices 1410, 1420 to provide remote control of the monitoring, diagnosis, and/or therapy functions of the medical devices 1410, 1420. [0128] In one embodiment, the patient's physician may access patient data transmitted from the medical devices 1410, 1420 to the patient information server 1430. After evaluation of the patient data, the patient's physician may communicate with one or more of the patient-internal or patient-external devices 1410, 1420 through the APM system 1440 to initiate, terminate, or modify the monitoring, diagnostic, and/or therapy functions of the patient-internal and/or patient-external medical systems 1410, 1420. Systems and methods involving advanced patient management techniques are further described in U.S. Pat. Nos. 6,336,903, 6,312,378, 6,270,457, and 6,398,728, hereby incorporated herein by reference. [0129] In another embodiment, the patient-internal and patient-external medical devices 1410, 1420 may not communicate directly, but may communicate indirectly through the APM system 1440. In this embodiment, the APM system 1440 may operate as an intermediary between two or more of the medical devices 1410, 1420. For example, data and/or control information may be transferred from one of the medical devices 1410, 1420 to the APM system 1440. The APM system 1440 may transfer the data and/or control information to another of the medical devices 1410, 1420. [0130] In one embodiment, the APM system 1440 may communicate directly with the patient-internal and/or patient-external medical devices 1410, 1420. In another embodiment, the APM system 1440 may communicate with the patient-internal and/or patient-external medical devices 1410, 1420 through medical device programmers 1460, 1470 respectively associated with each medical device 1410, 1420. [0131] Various embodiments described herein may be used in connection with advanced patient management. Methods, structures, and/or techniques described herein relating to advanced patient management, such as those involving remote patient/device monitoring, diagnosis, therapy, or other advanced patient management related methodologies, may incorporate features of one or more of the following references: U.S. Pat. Nos. 6,221,011; 6,277,072; 6,280,380; 6,358,203; 6,368,284; and 6,440,066 each hereby incorporated herein by reference. [0132] A number of the examples presented herein involve block diagrams illustrating functional blocks used for coordinated monitoring, diagnosis and/or therapy functions in accordance with embodiments of the invention. It will be understood by those skilled in the art that there exist many possible configurations in which these functional blocks may be arranged and implemented. The examples depicted herein provide examples of possible functional arrangements used to implement the approaches of the invention. [0133] Each feature disclosed in this specification (including any accompanying claims, abstract, and drawings), may be replaced by alternative features having the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features. [0134] Various modifications and additions can be made to the embodiments discussed hereinabove without departing from the scope of the present invention. Accordingly, the scope of the present invention should not be limited by the particular embodiments described above, but should be defined only by the claims set forth below and equivalents thereof. Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4365636 *Jun 19, 1981Dec 28, 1982Medicon, Inc.Method of monitoring patient respiration and predicting apnea therefromUS4813427 *Feb 17, 1987Mar 21, 1989Hellige GmbhApparatus and method for preventing hypoxic damageUS4827935 *Apr 24, 1986May 9, 1989Purdue Research FoundationDemand electroventilatorUS4830008 *Feb 16, 1988May 16, 1989Meer Jeffrey AMethod and system for treatment of sleep apneaUS5105354 *Jan 23, 1989Apr 14, 1992Nippon Kayaku Kabushiki KaishaMethod and apparatus for correlating respiration and heartbeat variabilityUS5123425 *Sep 6, 1990Jun 23, 1992EdentecObstructive sleep apnea collarUS5146918 *Mar 19, 1991Sep 15, 1992Medtronic, Inc.Demand apnea control of central and obstructive sleep apneaUS5178156 *Jun 12, 1990Jan 12, 1993Chest CorporationApnea preventive stimulating deviceUS5187657 *Apr 5, 1990Feb 16, 1993Hewlett-Packard CompanyCardiac analyzer with rem sleep detectionUS5211173 *Sep 21, 1992May 18, 1993Medtronic, Inc.Servo muscle controlUS5215082 *Apr 2, 1991Jun 1, 1993Medtronic, Inc.Implantable apnea generator with ramp on generatorUS5233983 *Sep 3, 1991Aug 10, 1993Medtronic, Inc.Method and apparatus for apnea patient screeningUS5335657 *May 3, 1991Aug 9, 1994Cyberonics, Inc.Therapeutic treatment of sleep disorder by nerve stimulationUS5353788 *Sep 21, 1992Oct 11, 1994Miles Laughton ECardio-respiratory control and monitoring system for determining CPAP pressure for apnea treatmentUS5466245 *Nov 15, 1994Nov 14, 1995Cardiac Pacemakers, Inc.Method and apparatus to continuously optimize the A-V delay in a dual chamber pacemakerUS5483969 *Sep 21, 1994Jan 16, 1996Medtronic, Inc.Method and apparatus for providing a respiratory effort waveform for the treatment of obstructive sleep apneaUS5485851 *Sep 21, 1994Jan 23, 1996Medtronic, Inc.Method and apparatus for arousal detectionUS5522862 *Sep 21, 1994Jun 4, 1996Medtronic, Inc.Method and apparatus for treating obstructive sleep apneaUS5549655 *Sep 21, 1994Aug 27, 1996Medtronic, Inc.Method and apparatus for synchronized treatment of obstructive sleep apneaUS5593431 *Mar 30, 1995Jan 14, 1997Medtronic, Inc.Medical service employing multiple DC accelerometers for patient activity and posture sensing and methodUS5645570 *Jun 17, 1994Jul 8, 1997Sorin Biomedica S.P.A.Method and device for monitoring and detecting sympatho-vagal activity and for providing therapy in response theretoUS5696522 *Dec 1, 1995Dec 9, 1997Sony CorporationPlasma driver circuit capable of surpressing surge current of plasma display channelUS5738102 *Jul 31, 1996Apr 14, 1998Lemelson; Jerome H.Patient monitoring systemUS5844680 *Sep 24, 1995Dec 1, 1998Byk-Gardner GmbhDevice and process for measuring and analysing spectral radiation, in particular for measuring and analysing color characteristicsUS5861011 *Feb 14, 1997Jan 19, 1999Vitatron Medical, B.V.Pacemaker with automatic lower rate limit dropUS5891023 *Jan 27, 1997Apr 6, 1999Lynn; Lawrence A.Apparatus for the diagnosis of sleep apneaUS5911218 *Mar 18, 1997Jun 15, 1999Dimarco; Anthony FortunatoMethod and apparatus for electrical stimulation of the respiratory muscles to achieve artificial ventilation in a patientUS5944680 *Jun 26, 1996Aug 31, 1999Medtronic, Inc.Respiratory effort detection method and apparatusUS5964778 *Mar 17, 1998Oct 12, 1999Medtronic, Inc.Balloon attachment at catheter tipUS5974340 *Apr 29, 1997Oct 26, 1999Cardiac Pacemakers, Inc.Apparatus and method for monitoring respiratory function in heart failure patients to determine efficacy of therapyUS5974349 *Dec 4, 1998Oct 26, 1999Levine; SeymourRemote, aircraft, global, paperless maintenance systemUS6044297 *Sep 25, 1998Mar 28, 2000Medtronic, Inc.Posture and device orientation and calibration for implantable medical devicesUS6064910 *Nov 25, 1997May 16, 2000Pacesetter AbRespirator rate/respiration depth detector and device for monitoring respiratory activity employing sameUS6076015 *Feb 27, 1998Jun 13, 2000Cardiac Pacemakers, Inc.Rate adaptive cardiac rhythm management device using transthoracic impedanceUS6091973 *Apr 11, 1996Jul 18, 2000Resmed LimitedMonitoring the occurrence of apneic and hypopneic arousalsUS6099479 *Jun 26, 1996Aug 8, 2000Medtronic, Inc.Method and apparatus for operating therapy systemUS6120441 *Oct 16, 1996Sep 19, 2000Map Medizintechnik Fur Arzt Und Patient GmbhMethod and device for quantitative analysis of sleep disturbancesUS6126611 *Jan 29, 1999Oct 3, 2000Medtronic, Inc.Apparatus for management of sleep apneaUS6128534 *Jun 16, 1998Oct 3, 2000Pacesetter, Inc.Implantable cardiac stimulation device and method for varying pacing parameters to mimic circadian cyclesUS6132384 *Jun 26, 1996Oct 17, 2000Medtronic, Inc.Sensor, method of sensor implant and system for treatment of respiratory disordersUS6141590 *Sep 25, 1997Oct 31, 2000Medtronic, Inc.System and method for respiration-modulated pacingUS6240316 *Aug 6, 1999May 29, 2001Advanced Bionics CorporationImplantable microstimulation system for treatment of sleep apneaUS6251126 *Oct 4, 1999Jun 26, 2001Medtronic IncMethod and apparatus for synchronized treatment of obstructive sleep apneaUS6269269 *Oct 4, 1999Jul 31, 2001Medtronic Inc.Method and apparatus for synchronized treatment of obstructive sleep apneaUS6272377 *Oct 1, 1999Aug 7, 2001Cardiac Pacemakers, Inc.Cardiac rhythm management system with arrhythmia prediction and preventionUS6275727 *Nov 4, 1999Aug 14, 2001Cardiac Pacemakers, Inc.Implantable cardiac rhythm management device for assessing status of CHF patientsUS6363270 *Dec 16, 1999Mar 26, 2002Resmed LimitedMonitoring the occurrence of apneic and hypopneic arousalsUS6409675 *Nov 10, 1999Jun 25, 2002Pacesetter, Inc.Extravascular hemodynamic monitorUS6415183 *Dec 9, 1999Jul 2, 2002Cardiac Pacemakers, Inc.Method and apparatus for diaphragmatic pacingUS6431171 *May 7, 1997Aug 13, 2002Compumedics, LtdControlliing gas or drug delivery to patientUS6438407 *Mar 20, 2000Aug 20, 2002Medtronic, Inc.Method and apparatus for monitoring physiologic parameters conjunction with a treatmentUS6480733 *Dec 17, 1999Nov 12, 2002Pacesetter, Inc.Method for monitoring heart failureUS6527729 *Oct 11, 2000Mar 4, 2003Pacesetter, Inc.Method for monitoring patient using acoustic sensorUS6574507 *Jul 5, 1999Jun 3, 2003Ela Medical S.A.Active implantable medical device for treating sleep apnea syndrome by electrostimulationUS6589188 *May 5, 2000Jul 8, 2003Pacesetter, Inc.Method for monitoring heart failure via respiratory patternsUS6600949 *May 5, 2000Jul 29, 2003Pacesetter, Inc.Method for monitoring heart failure via respiratory patternsUS6633135 *Jul 3, 2001Oct 14, 2003Wintest CorporationApparatus and method for evaluating organic EL displayUS6641542 *Apr 26, 2002Nov 4, 2003Medtronic, Inc.Method and apparatus to detect and treat sleep respiratory eventsUS6658292 *Aug 24, 2001Dec 2, 2003Pacesetter, Inc.Detection of patient's position and activity status using 3D accelerometer-based position sensorUS6677925 *Sep 6, 2000Jan 13, 2004Sharp Kabushiki KaishaActive-matrix-type liquid crystal display device, data signal line driving circuit, and liquid crystal display device driving methodUS6741885 *Jul 17, 2001May 25, 2004Pacesetter, Inc.Implantable cardiac device for managing the progression of heart disease and methodUS6752765 *Nov 17, 2000Jun 22, 2004Medtronic, Inc.Method and apparatus for monitoring heart rate and abnormal respirationUS6773404 *Dec 5, 2002Aug 10, 2004Ela Medical S.A.Discriminating between an awake phase and a sleep phase of a patient in an active implantable medical deviceUS6873117 *Sep 29, 2003Mar 29, 2005Pioneer CorporationDisplay panel and display deviceUS6961053 *Nov 3, 1999Nov 1, 2005Tanita CorporationLCD display device with display density adjusting functionUS20010018547 *Jan 17, 2001Aug 30, 2001Mechlenburg Douglas M.Muscle stimulating device and method for diagnosing and treating a breathing disorderUS20020193697 *Apr 26, 2002Dec 19, 2002Cho Yong KyunMethod and apparatus to detect and treat sleep respiratory eventsUS20020193839 *Jun 7, 2001Dec 19, 2002Cho Yong KyunMethod for providing a therapy to a patient involving modifying the therapy after detecting an onset of sleep in the patient, and implantable medical device embodying sameUS20030023184 *Jul 23, 2001Jan 30, 2003Jonathan Pitts-CrickMethod and system for diagnosing and administering therapy of pulmonary congestionUS20030055461 *Aug 6, 2002Mar 20, 2003Girouard Steven D.Cardiac rhythm management systems and methods predicting congestive heart failure statusUS20030100925 *Nov 28, 2001May 29, 2003Medtronic, Inc.Implantable medical device for measuring mechanical heart functionUS20030153953 *Feb 14, 2002Aug 14, 2003Euljoon ParkStimulation device for sleep apnea prevention, detection and treatmentUS20030153954 *Feb 14, 2002Aug 14, 2003Euljoon ParkSleep apnea therapy device using dynamic overdrive pacingUS20030153955 *Feb 14, 2002Aug 14, 2003Euljoon ParkCardiac stimulation device including sleep apnea prevention and treatmentUS20030153956 *Sep 18, 2002Aug 14, 2003Euljoon ParkCardiac stimulation device including sleep apnea prevention and treatmentUS20030163059 *Dec 5, 2002Aug 28, 2003Yann PoezeveraDiscriminating between an awake phase and a sleep phase of a patient in an active implantable medical deviceUS20030195571 *Apr 12, 2002Oct 16, 2003Burnes John E.Method and apparatus for the treatment of central sleep apnea using biventricular pacingUS20030199945 *Feb 10, 2003Oct 23, 2003James CiullaDevice and method for treating disordered breathingUS20030204213 *Apr 30, 2002Oct 30, 2003Jensen Donald N.Method and apparatus to detect and monitor the frequency of obstructive sleep apneaUS20030216789 *May 6, 2003Nov 20, 2003The Foundry, Inc.Method and system for treating sleep apneaUS20040002742 *Jun 27, 2002Jan 1, 2004Florio Joseph J.Using activity-based rest disturbance as a metric of sleep apneaUS20040030362 *Mar 12, 2003Feb 12, 2004Hill Michael R. S.Method and device for electronically controlling the beating of a heartUS20040059240 *Sep 15, 2003Mar 25, 2004Medtronic, Inc.Method and apparatus to detect and treat sleep respiratory eventsUS20040088027 *Oct 31, 2002May 6, 2004Burnes John E.Aggregation of data from external data sources within an implantable medical deviceUS20040133079 *Jan 2, 2003Jul 8, 2004Mazar Scott ThomasSystem and method for predicting patient health within a patient management systemUS20040138719 *Apr 21, 2003Jul 15, 2004Cho Yong K.System and method for automatically monitoring and delivering therapy for sleep-related disordered breathingUS20040176809 *Dec 15, 2003Sep 9, 2004Medtronic, Inc.Method and apparatus for modifying delivery of a therapy in response to onset of sleepUS20050043772 *Aug 18, 2003Feb 24, 2005Stahmann Jeffrey E.Therapy triggered by prediction of disordered breathing* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS7359837Apr 27, 2006Apr 15, 2008Medtronic, Inc.Peak data retention of signal data in an implantable medical deviceUS7385443Jan 31, 2007Jun 10, 2008Medtronic, Inc.Chopper-stabilized instrumentation amplifierUS7391257Jan 31, 2007Jun 24, 2008Medtronic, Inc.Chopper-stabilized instrumentation amplifier for impedance measurementUS7610083Apr 27, 2006Oct 27, 2009Medtronic, Inc.Method and system for loop recording with overlapping eventsUS7622988Mar 28, 2008Nov 24, 2009Medtronic, Inc.Chopper-stabilized instrumentation amplifier for impedance measurementUS7623053Sep 26, 2007Nov 24, 2009Medtronic, Inc.Implantable medical device with low power delta-sigma analog-to-digital converterUS7714757Sep 26, 2007May 11, 2010Medtronic, Inc.Chopper-stabilized analog-to-digital converterUS7720548Apr 28, 2006May 18, 2010MedtronicImpedance-based stimulation adjustmentUS7764988Apr 27, 2006Jul 27, 2010Medtronic, Inc.Flexible memory management scheme for loop recording in an implantable deviceUS7765088Feb 26, 2008Jul 27, 2010Medtronic, Inc.Peak data retention of signal data in an implantable medical deviceUS7847628May 15, 2008Dec 7, 2010Medtronic, Inc.Chopper-stabilized instrumentation amplifierUS7865244Dec 19, 2005Jan 4, 2011Medtronic, Inc.System and method for regulating cardiopulmonary triggered therapy to the brainUS7899545Oct 31, 2007Mar 1, 2011Michael Sasha JohnMethods and systems for semi-automatic adjustment of medical monitoring and treatmentUS7917199Apr 26, 2006Mar 29, 2011Medtronic, Inc.Patient event marking in combination with physiological signalsUS7945316Dec 19, 2005May 17, 2011Medtronic, Inc.System and method for monitoring or treating nervous system disordersUS8000788 *Apr 27, 2007Aug 16, 2011Medtronic, Inc.Implantable medical device for treating neurological conditions including ECG sensingUS8024029Nov 2, 2005Sep 20, 2011Medtronic, Inc.Techniques for user-activated data retention in an implantable medical deviceUS8041418Dec 19, 2005Oct 18, 2011Medtronic, Inc.System and method for regulating cardiac triggered therapy to the brainUS8041419Dec 19, 2005Oct 18, 2011Medtronic, Inc.System and method for monitoring or treating nervous system disordersUS8068911Apr 27, 2007Nov 29, 2011Medtronic, Inc.System and method for regulating cardiopulmonary triggered therapy to the brainUS8108033Nov 2, 2005Jan 31, 2012Medtronic, Inc.Techniques for data retention upon detection of an event in an implantable medical deviceUS8108038Apr 27, 2006Jan 31, 2012Medtronic, Inc.System and method for segmenting a cardiac signal based on brain activityUS8108046Jun 22, 2007Jan 31, 2012Medtronic, Inc.System and method for using cardiac events to trigger therapy for treating nervous system disordersUS8108049Apr 28, 2006Jan 31, 2012Medtronic, Inc.Impedance-based stimulation adjustmentUS8112148Jun 22, 2007Feb 7, 2012Medtronic, Inc.System and method for monitoring cardiac signal activity in patients with nervous system disordersUS8112153Apr 27, 2007Feb 7, 2012Medtronic, Inc.System and method for monitoring or treating nervous system disordersUS8121694Sep 25, 2008Feb 21, 2012Medtronic, Inc.Therapy control based on a patient movement stateUS8121702Mar 4, 2010Feb 21, 2012Medtronic, Inc.Impedance-based stimulation adjustmentUS8172766 *Nov 4, 2005May 8, 2012Cleveland Medical Devices Inc.Integrated sleep diagnosis and treatment device and methodUS8190251Nov 30, 2006May 29, 2012Medtronic, Inc.Method and apparatus for the treatment of movement disordersUS8209009Apr 27, 2007Jun 26, 2012Medtronic, Inc.System and method for segmenting a cardiac signal based on brain stimulationUS8209019 *Apr 27, 2007Jun 26, 2012Medtronic, Inc.System and method for utilizing brain state information to modulate cardiac therapyUS8214035 *Apr 27, 2007Jul 3, 2012Medtronic, Inc.System and method for utilizing brain state information to modulate cardiac therapyUS8224431Nov 2, 2005Jul 17, 2012Medtronic, Inc.Techniques for selective channel processing and data retention in an implantable medical deviceUS8265769Jan 31, 2007Sep 11, 2012Medtronic, Inc.Chopper-stabilized instrumentation amplifier for wireless telemetryUS8290596Sep 25, 2008Oct 16, 2012Medtronic, Inc.Therapy program selection based on patient stateUS8354881Dec 2, 2010Jan 15, 2013Medtronic, Inc.Chopper-stabilized instrumentation amplifierUS8380314Oct 16, 2007Feb 19, 2013Medtronic, Inc.Patient directed therapy controlUS8478402Oct 31, 2008Jul 2, 2013Medtronic, Inc.Determining intercardiac impedanceUS8478417Nov 2, 2005Jul 2, 2013Medtronic, Inc.Techniques for data reporting in an implantable medical deviceUS8483839Feb 23, 2012Jul 9, 2013Medtronic, Inc.Activity sensing for stimulator controlUS8485979Apr 27, 2007Jul 16, 2013Medtronic, Inc.System and method for monitoring or treating nervous system disordersUS8554325Jan 6, 2012Oct 8, 2013Medtronic, Inc.Therapy control based on a patient movement stateUS8565886Nov 3, 2011Oct 22, 2013Medtronic, Inc.Arousal state modulation with electrical stimulationUS8594779Apr 30, 2007Nov 26, 2013Medtronic, Inc.Seizure predictionUS8649860May 17, 2010Feb 11, 2014Cardiac Pacemakers, Inc.Adaptive event storage in implantable deviceUS8706181Jan 25, 2012Apr 22, 2014Medtronic, Inc.Target therapy delivery site selectionUS8733347 *Jul 5, 2007May 27, 2014Universite Pierre Et Marie Curie-Paris ViDevice for detecting the improper adjustment of a ventilatory support machine used on a mammalUS8744562Dec 10, 2010Jun 3, 2014Medtronic, Inc.Method for monitoring or treating nervous system disordersUS8761868Dec 10, 2010Jun 24, 2014Medtronic, Inc.Method for monitoring or treating nervous system disordersUS8768446Apr 26, 2006Jul 1, 2014Medtronic, Inc.Clustering with combined physiological signalsUS8781595Apr 30, 2007Jul 15, 2014Medtronic, Inc.Chopper mixer telemetry circuitUS8788044Jan 20, 2006Jul 22, 2014Michael Sasha JohnSystems and methods for tissue stimulation in medical treatmentUS8821397Sep 27, 2011Sep 2, 2014Masimo CorporationDepth of consciousness monitor including oximeterUS8825175Jan 12, 2012Sep 2, 2014Medtronic, Inc.Impedance-based stimulation adjustmentUS8831735Oct 31, 2007Sep 9, 2014Michael Sasha JohnMethods and systems for semi-automatic adjustment of medical monitoring and treatmentUS8831737May 31, 2013Sep 9, 2014Medtronic, Inc.Activity sensing for stimulator controlUS8914115Jul 26, 2010Dec 16, 2014Medtronic, Inc.Selecting therapy cycle parameters based on monitored brain signalUS8938299Nov 19, 2009Jan 20, 2015Inspire Medical Systems, Inc.System for treating sleep disordered breathingUS8948862 *Mar 11, 2010Feb 3, 2015Toyota Jidosha Kabushiki KaishaStimulatory effect estimation device, sleep depth estimation device, stimulatory effect estimation method, and vehicle control deviceUS8965509Oct 31, 2007Feb 24, 2015Michael Sasha JohnMethods and systems for semi-automatic adjustment of medical monitoring and treatmentUS8983572Oct 28, 2011Mar 17, 2015Inspire Medical Systems, Inc.System and method for patient selection in treating sleep disordered breathingUS8983591Oct 17, 2011Mar 17, 2015Brain Sentinel, Inc.Method and apparatus for detecting seizuresUS9014804Jun 10, 2011Apr 21, 2015Medtronic, Inc.Implantable medical device for treating neurological conditions including ECG sensingUS9016565 *Feb 6, 2013Apr 28, 2015Dylan T X ZhouWearable personal digital device for facilitating mobile device payments and personal useUS9037254Oct 31, 2007May 19, 2015Michael Sasha JohnMethods and systems for semi-automatic adjustment of medical monitoring and treatmentUS9072870Sep 25, 2008Jul 7, 2015Medtronic, Inc.Sleep stage detectionUS9089270 *Jun 28, 2012Jul 28, 2015Lg Electronics Inc.Terminal and control method thereofUS9089713Oct 24, 2007Jul 28, 2015Michael Sasha JohnMethods and systems for semi-automatic adjustment of medical monitoring and treatmentUS9114256 *Jan 31, 2012Aug 25, 2015Torytrans, S.LElectrostimulation method and system for the treatment of sleep apneaUS9186105Jul 5, 2012Nov 17, 2015Brain Sentinel, Inc.Method and apparatus for detecting seizuresUS9197173Oct 14, 2009Nov 24, 2015Medtronic, Inc.Chopper-stabilized instrumentation amplifier for impedance measurementUS9211411Aug 17, 2011Dec 15, 2015Medtronic, Inc.Therapy for rapid eye movement behavior disorder (RBD)US9248288Jan 14, 2013Feb 2, 2016Medtronic, Inc.Patient directed therapy controlUS9259177Aug 5, 2014Feb 16, 2016Medtronic, Inc.Techniques for data retention upon detection of an event in an implantable medical deviceUS9333350 *Apr 17, 2009May 10, 2016Medtronic, Inc.Psychiatric disorder therapy controlUS9339658Feb 5, 2014May 17, 2016Cardiac Pacemakers, Inc.Adaptive event storage in implantable deviceUS9364679May 19, 2015Jun 14, 2016Michael Sasha JohnSystem for providing therapy to a patientUS9439150Apr 12, 2013Sep 6, 2016Medtronic, Inc.Control of spectral agressors in a physiological signal montoring deviceUS9449501Jun 4, 2014Sep 20, 2016Medtronics, Inc.Chopper mixer telemetry circuitUS9486628Mar 30, 2010Nov 8, 2016Inspire Medical Systems, Inc.Percutaneous access for systems and methods of treating sleep apneaUS9521979Apr 12, 2013Dec 20, 2016Medtronic, Inc.Control of spectral agressors in a physiological signal monitoring deviceUS9533114Aug 26, 2013Jan 3, 2017Cleveland Medical Devices Inc.Integrated diagnostic and therapeutic system and method for improving treatment of subject with complex and central sleep apneaUS9538949Aug 27, 2014Jan 10, 2017Masimo CorporationDepth of consciousness monitor including oximeterUS9566447Dec 28, 2005Feb 14, 2017Cardiac Pacemakers, Inc.Neural stimulation system for reducing atrial proarrhythmiaUS9613184Apr 17, 2009Apr 4, 2017Medtronic, Inc.Analyzing a washout period characteristic for psychiatric disorder therapy deliveryUS9615744Aug 31, 2010Apr 11, 2017Medtronic, Inc.Chopper-stabilized instrumentation amplifier for impedance measurementUS9615773 *Aug 13, 2008Apr 11, 2017Cleveland Medical Devices Inc.Method and device for sleep analysis and therapyUS20060094970 *Nov 2, 2005May 4, 2006Medtronic, Inc.Techniques for selective channel processing and data retention in an implantable medical deviceUS20060094971 *Nov 2, 2005May 4, 2006Medtronic, Inc.Techniques for data retention upon detection of an event in an implantable medical deviceUS20060094972 *Nov 2, 2005May 4, 2006Medtronic, Inc.Techniques for user-activated data retention in an implantable medical deviceUS20060095092 *Nov 2, 2005May 4, 2006Medtronic, Inc.Techniques for data reporting in an implantable medical deviceUS20060135877 *Dec 19, 2005Jun 22, 2006Medtronic, Inc.System and method for monitoring or treating nervous system disordersUS20060149337 *Jan 20, 2006Jul 6, 2006John Michael SSystems and methods for tissue stimulation in medical treatmentUS20060195039 *Apr 26, 2006Aug 31, 2006Medtronic, Inc.Clustering with combined physiological signalsUS20060195144 *Dec 19, 2005Aug 31, 2006Medtronic, Inc.System and method for regulating cardiopulmanary triggered therapy to the brainUS20060224067 *Apr 27, 2006Oct 5, 2006Medtronic, Inc.System and method for segmenting a cardiac signal based on brain activityUS20060235489 *Apr 26, 2006Oct 19, 2006Medtronic, Inc.Patient event marking in combination with physiological signalsUS20060253174 *Apr 28, 2006Nov 9, 2006Medtronic, Inc.Impedance-based stimulation adjustmentUS20060259079 *Apr 28, 2006Nov 16, 2006Medtronic, Inc.Impedance-based stimulation adjustmentUS20070150011 *Dec 28, 2005Jun 28, 2007Meyer Scott ANeural stimulation system for reducing atrial proarrhythmiaUS20070225674 *Nov 30, 2006Sep 27, 2007Medtronic, Inc.Method and Apparatus for the Treatment of Movement DisordersUS20070238939 *Apr 27, 2007Oct 11, 2007Medtronic, Inc.System and method for monitoring or treating nervous system disordersUS20070239054 *Apr 27, 2007Oct 11, 2007Medtronic, Inc.System and method for monitoring or treating nervous system disordersUS20070239060 *Apr 27, 2007Oct 11, 2007Medtronic, Inc.System and method for regulating cardiac triggered therapy to the brainUS20070255155 *Apr 27, 2006Nov 1, 2007Medtronic, Inc.Method and system for loop recording with overlapping eventsUS20070255531 *Apr 27, 2006Nov 1, 2007Medtronic, Inc.Peak data retention of signal data in an implantable medical deviceUS20070260147 *Jun 22, 2007Nov 8, 2007Medtronic, Inc.System and method for monitoring cardiac signal activity in patients with nervous system disordersUS20070260286 *Apr 27, 2007Nov 8, 2007Giftakis Jonathon ESystem and method for utilizing brain state information to modulate cardiac therapyUS20070265536 *Apr 27, 2007Nov 15, 2007Giftakis Jonathon ESystem and method for segmenting a cardiac signal based on brain stimulationUS20070265677 *Apr 27, 2007Nov 15, 2007Giftakis Jonathon ESystem and method for utilizing brain state information to modulate cardiac therapyUS20080033490 *Apr 27, 2007Feb 7, 2008Medtronic, Inc.System and method for regulating cardiopulmonary triggered therapy to the brainUS20080058773 *Oct 24, 2007Mar 6, 2008John Michael SMethods and Systems for semi-automatic adjustment of medical monitoring and treatment.US20080061961 *Oct 31, 2007Mar 13, 2008John Michael SMethods and Systems for semi-automatic adjustment of medical monitoring and treatment.US20080097553 *Oct 31, 2007Apr 24, 2008John Michael SMethods and Systems for semi-automatic adjustment of medical monitoring and treatmentUS20080109050 *Oct 31, 2007May 8, 2008John Michael SMethods and systems for semi-automatic adjustment of medical monitoring and treatmentUS20080183098 *Mar 28, 2008Jul 31, 2008Medtronic, Inc.Chopper-stabilized instrumentation amplifier for impedance measurementUS20080211574 *May 15, 2008Sep 4, 2008Medtronic, Inc.Chopper-stabilized instrumentation amplifierUS20080235469 *Feb 26, 2008Sep 25, 2008Medtronic, Inc.Peak Data Retention of Signal Data In An Implantable Medical DeviceUS20080269630 *Apr 30, 2007Oct 30, 2008Medtronic, Inc.Seizure predictionUS20080269631 *Apr 30, 2007Oct 30, 2008Medtronic, Inc.Seizure predictionUS20080269841 *Apr 30, 2007Oct 30, 2008Medtronic, Inc.Chopper mixer telemetry circuitUS20080269842 *Apr 27, 2007Oct 30, 2008Giftakis Jonathon EImplantable medical device for treating neurological conditions with an initially disabled cardiac therapy port and leadless ECG sensingUS20080288023 *Aug 30, 2006Nov 20, 2008Michael Sasha JohnMedical treatment using patient states, patient alerts, and hierarchical algorithmsUS20090079606 *Sep 26, 2007Mar 26, 2009Terry Michael BImplantable medical device with low power delta-sigma analog-to-digital converterUS20090079607 *Sep 26, 2007Mar 26, 2009Medtronic, Inc.Chopper-stabilized analog-to-digital converterUS20090082639 *Sep 15, 2008Mar 26, 2009Pittman Stephen DAutomated Sleep PhenotypingUS20090082691 *Sep 25, 2008Mar 26, 2009Medtronic, Inc.Frequency selective monitoring of physiological signalsUS20090082829 *Oct 16, 2007Mar 26, 2009Medtronic, Inc.Patient directed therapy controlUS20090099627 *Sep 25, 2008Apr 16, 2009Medtronic, Inc.Therapy control based on a patient movement stateUS20090105785 *Sep 25, 2008Apr 23, 2009Medtronic, Inc.Therapy program selectionUS20090192556 *Sep 25, 2008Jul 30, 2009Medtronic, Inc.Sleep stage detectionUS20090241946 *Jul 5, 2007Oct 1, 2009Universite Pierre Et Marie Curie-Paris ViDevice for detecting the improper adjustment of a ventilatory support machine used on a mammalUS20090264789 *Apr 28, 2009Oct 22, 2009Medtronic, Inc.Therapy program selectionUS20090264955 *Apr 17, 2009Oct 22, 2009Medtronic, Inc.Analyzing a stimulation period characteristic for psychiatric disorder therapy deliveryUS20090264956 *Apr 17, 2009Oct 22, 2009Medtronic, Inc.Psychiatric disorder therapy controlUS20090264957 *Apr 17, 2009Oct 22, 2009Medtronic, Inc.Analyzing a washout period characteristic for psychiatric disorder therapy deliveryUS20090264967 *Apr 17, 2009Oct 22, 2009Medtronic, Inc.Timing therapy evaluation trialsUS20100113964 *Oct 31, 2008May 6, 2010Wahlstrand John DDetermining intercardiac impedanceUS20100114223 *Oct 31, 2008May 6, 2010Wahlstrand John DDetermining intercardiac impedanceUS20100161007 *Mar 4, 2010Jun 24, 2010Medtronic, Inc.Impedance-based stimulation adjustmentUS20110068861 *Dec 2, 2010Mar 24, 2011Medtronic, Inc.Chopper-stabilized instrumentation amplifierUS20110112590 *Nov 11, 2009May 12, 2011Medtronic, Inc.Deep brain stimulation for sleep and movement disordersUS20110137371 *Jul 26, 2010Jun 9, 2011Medtronic, Inc.Selecting therapy cycle parameters based on monitored brain signalUS20120253221 *Mar 11, 2010Oct 4, 2012Toyota Jidosha Kabushiki KaishaStimulatory effect estimation device, sleep depth estimation device, stimulatory effect estimation method, and vehicle control deviceUS20120330114 *Feb 14, 2011Dec 27, 2012Koninklijke Philips Electronics N.V.System and method for obtaining an objective measure of dyspneaUS20130005303 *Jun 28, 2012Jan 3, 2013Song SeungkyuTerminal and control method thereofUS20130146659 *Feb 6, 2013Jun 13, 2013Dylan T X ZhouWearable personal digital device for facilitating mobile device payments and personal useUS20140076318 *Nov 20, 2013Mar 20, 2014Resmed LimitedMethod and apparatus for assessing sleep qualityUS20150018895 *Jan 31, 2012Jan 15, 2015Torytrans, S.L.Electrostimulation method and system for the treatment of sleep apneaUS20160206875 *Mar 30, 2016Jul 21, 2016Pacesetter, Inc.Neurostimulation method and system to treat apneaCN102711887A *Dec 17, 2010Oct 3, 2012皇家飞利浦电子股份有限公司Servo ventilation using pressure drop from baselineCN103153184A *Aug 15, 2011Jun 12, 2013呼吸运动公司Devices and methods for respiratory variation monitoring by measurement of respiratory volumes, motion and variabilityEP2324883A1 *Nov 17, 2006May 25, 2011Cardiac Pacemakers, Inc.Neural stimulation system for reducing atrial proarrhythmiaWO2006050524A1 *Nov 2, 2005May 11, 2006Medtronic, Inc.Techniques for data retention upon detection of an event in an implantable medical deviceWO2006119015A1 *Apr 28, 2006Nov 9, 2006Medtronic, Inc.Impedance-based stimulation adjustmentWO2006119046A1 *Apr 28, 2006Nov 9, 2006Medtronic, Inc.Impedance-based stimulation adjustmentWO2007075232A1 *Nov 17, 2006Jul 5, 2007Cardiac Pacemakers, Inc.Neural stimulation system for reducing atrial proarrhythmiaWO2009002237A1 *Jun 27, 2007Dec 31, 2008St. Jude Medical AbA method and device for detecting rem sleepWO2009042379A1 *Sep 9, 2008Apr 2, 2009Medtronic, Inc.Patient directed therapy controlWO2009094050A1 *Sep 25, 2008Jul 30, 2009Medtronic, Inc.Sleep stage detectionWO2009129480A3 *Apr 17, 2009Mar 25, 2010Medtronic, Inc.Psychiatric disorder therapy control* Cited by examinerClassifications U.S. Classification128/200.24, 128/204.23, 607/9International ClassificationA61M16/10, A61N1/36, A61M15/00, A61M16/00, A61B5/04, A61B5/11Cooperative ClassificationA61B5/4094, A61N1/36135, A61N1/36114, A61N1/3611, A61B5/1107, A61M2230/10, A61N1/36514, A61B5/4818, A61M2205/3561, A61M2230/63, A61M2016/0039, A61M2230/04, A61M16/10, A61B5/04012, A61M2205/3584, A61N1/3601, A61M16/0051, A61M2016/0042, A61B2505/09, A61B5/6869European ClassificationA61B5/48C8, A61N1/36Z, A61M16/00K, A61N1/36, A61B5/04R, A61M16/10, A61B5/11J, A61N1/36C, A61N1/365BLegal EventsDateCodeEventDescriptionDec 29, 2004ASAssignmentOwner name: CARDIAC PACEMAKERS, INC., MINNESOTAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, KENT;STAHMANN, JEFFREY E.;HARTLEY, JESSE W.;AND OTHERS;REEL/FRAME:015506/0717;SIGNING DATES FROM 20041115 TO 20041118Owner name: CARDIAC PACEMAKERS, INC.,MINNESOTAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, KENT;STAHMANN, JEFFREY E.;HARTLEY, JESSE W.;AND OTHERS;SIGNING DATES FROM 20041115 TO 20041118;REEL/FRAME:015506/0717Dec 28, 2010CCCertificate of correctionMar 14, 2013FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services